It's been a busy week for Janssen Pharmaceuticals Inc., which picked up a breakthrough therapy status for one of its candidates and requested a priority review for an sBLA.
Two companies picked up orphan drug designations from FDA: Tivorsan Pharmaceuticals Inc.'s Duchene muscular dystrophy candidate TVN-102 and







